Background: Encouraging responses to histone deacetylase inhibitors have been reported for hematologic malignancies. Here, we report effects of panobinostat and 5-azacytidine on the proliferation of juvenile myelomonocytic leukemia (JMML) CD34 + cells. Panobinostat, however, failed to influence the ability of AGM-S3 cells to stimulate JMML CD34 + cell production. In contrast to HL60 cells, apoptosis and cell cycle arrest in panobinostat-mediated inhibition were at low levels in JMML. The inhibitor also suppressed the factor-dependent proliferation of normal CD34 + cells on AGM-S3 cells. Meanwhile, no substantial inhibitory effects of 5-azacytidine on the growth of JMML CD34 + cells were observed.
INTRODUCTION
Juvenile myelomonocytic leukemia (JMML) is a fatal, mixed myelo- Abbreviations: AGM, aorta-gonad-mesonephros; CB, cord blood; JMML, juvenile myelomonocytic leukemia; SCF, stem cell factor; TPO, thrombopoietin mutations are common, recurrent secondary events associated with poor clinical outcomes in this disorder. 2 Our genetic analysis of individual granulocyte-macrophage colonies revealed that these non-RAS pathway gene mutations may represent the second genetic aberration in a proportion of children affected by JMML with PTPN 11 mutations. 3 Using droplet digital PCR, Stieglitz et al. detected SETBP1 mutations in approximately 30% of patients with JMML, suggesting that subclonal mutations at diagnosis confer a dismal prognosis in JMML. 4 More recently, Caye et al. reported multiple concomitant genetic hits targeting the RAS pathway and new pathway activation involving phosphoinositide 3-kinase and mTORC2 complex through RAC2 mutation. 5 In addition, their study defined PRC2 loss that switches the methylation/acetylation status of histone H3 lysine 27.
We previously reported that the percentage of patients with JMML who had p15 hypermethylation was less than 20%. 6 Subsequent studies elucidated frequent hypermethylation of significant numbers of genes in this disorder. Olk-Batz et al. identified that CpG islands of BMP4, CALCA, CDKN2B, and RARB genes were frequently hypermethylated in 127 JMML cases. 7 They found that a high methylation phenotype characterizes an aggressive biologic variant of JMML and is an important molecular predictor of the outcome. Epigenetic silencing also occurs in the a-kinase anchor protein 12 (AKAP12) gene, whose product functions as a regulator of protein kinase A and C signaling, acting downstream of RAS. 8 Cseh et al. reported that complete clinical, cytogenetic, and/or molecular genetic remissions before allogeneic hematopoietic stem cell transplantation were achieved by treatment with low-dose azacytidine (a DNA methyltransferase inhibitor) in three of 12 patients with JMML. 9 Histone deacetylase (HDAC) inhibitors are a class of antineoplastic agents targeting the epigenome, specifically chromatin remodeling, resulting in modulation of genes responsible for apoptosis and cell cycle regulation, and also hyperacetylation of many nonhistone pro- Maiso et al. reported that to improve the potency of HDAC inhibitors, the agents that act on cells at nanomolar concentrations are more effective than those acting on cells at micromolar concentrations. 12 Additionally, safety to pediatric patients is important for clinical use of an anticancer drug. 13 Accordingly, we selected panobinostat as an HDAC inhibitor that met the two criteria. We previously reported that stimulation of JMML CD34 + cells with stem cell factor (SCF) and thrombopoietin (TPO) during culture on AGM-S3 cells led to substantial expansion of JMML CD34 + cells that contained leukemic stem cells capable of transplantation into immunodeficient mice after 7 days culture. 14 Using this culture system, we evaluated effects of panobinostat on the proliferation of JMML CD34 + peripheral blood (PB) cells and compared with effects of 5-azacytidine.
MATERIALS AND METHODS
This study was approved by the institutional review board of Shinshu University School of Medicine. Informed consent was obtained from the guardians of the patients following institutional guidelines. 
Cell preparation

Reagents
Panobinostat (Wako Pure Chemical Industries, Ltd, Osaka, Japan) and 5-azacytidine (Sigma Chemical, St. Louis, MO) were dissolved in dimethyl sulfoxide, and then diluted with alpha medium. The plates were incubated at 37 • C in a humidified atmosphere flushed with 5% CO 2 in air. On day 7, the number of viable cells was determined by a trypan-blue exclusion test. When the cultures were performed up to day 14 or 28, half of the culture medium was replaced every 3 days with fresh medium containing the growth factors.
Suspension cultures
Effects of panobinostat or 5-azacytidine on stromal cell function
To examine effects of panobinostat on the stimulatory ability of AGM-S3 cells to generate JMML CD34 + cells, irradiated confluent AGM-S3 cells were cultured with or without 40 nM of panobinostat for 7 days, and then JMML CD34 + cells were seeded with SCF+TPO on the stromal cells rinsed off the reagent with the culture medium. 5-Azacytidine was used at a concentration of 8 M.
Flow cytometric analysis
The analysis of surface expression of CD14, CD15, and CD38 on the progenies generated from JMML CD34 + cells was performed, as described previously. 14 To examine apoptosis and cell cycle, we performed flow cytometric analysis after annexin V/propidium iodide (PI) double staining (Annexin A5-FITC Kit-Apoptosis Detection Kit; Beckman Coulter, Brea, CA), and after staining with 5 ′ -bromo-2 ′ -deoxyuridine (BrdU) and 7-aminoactinomycin D (7-AAD; BrdU Flow Kit; BD Pharmingen TM , Santiago, CA).
FISH analysis
FISH analysis was performed, using probes specific for the centromere of chromosome 7 and for the centromere of chromosome 8 according to a procedure described previously. 15 
TA B L E 1 Genetic and chromosomal characteristics of eight children with JMML
Statistical analysis
Values are expressed as means ± SD. To determine the significance of differences, we used one-way analysis of variance, followed by post hoc contrasts with Bonferroni limitation. The sensitivity to the reagent between JMML CD34 + CD38 − cells and CD34 + CD38 + cells was analyzed using the paired t-test. The chi-squared test was used to examine effects of the reagents on the growth of progenies with abnormal karyotype. All statistical analyses were performed with EZR, 16 and statistical significance was defined as P < 0.05.
RESULTS
Effects of panobinostat or 5-azacytidine on the growth of HL-60 and THP-1 cells
We Table 1) expanded to approximately 9.1 ± 7.8 (1.7-22.6)-fold the initial number after 7 days of culture. As presented in Figure 1A 
Effects of panobinostat or 5-azacytidine on the proliferation of JMML CD34
Effects of panobinostat on the stimulatory ability of AGM-S3 cells to generate JMML CD34 + cells
To evaluate the possibility that panobinostat decreased proliferation of JMML CD34 + cells via stromal cell dysfunction, AGM-S3 cells were incubated with or without 50 nM of the reagent. After 7 days of culture, the viability of AGM-S3 cells was higher than 80% in both conditions.
We then examined whether panobinostat influenced the stimulatory ability of AGM-S3 cells to generate JMML CD34 + cells. Irradiated AGM-S3 cells were cultured with or without 40 nM of panobinostat for 7 days, and then JMML CD34 + cells were seeded with SCF+TPO on the stromal cells rinsed off the reagent with the culture medium. As presented in Figure 2 , there was no significant difference in numbers 
Effects of panobinostat on apoptosis, cell cycle, and differentiation of progenies generated from CD34 + cells on AGM-S3 cells in the presence of SCF+TPO
We then evaluated influence of panobinostat on apoptosis, cell cycle, and differentiation of progenies generated from JMML CD34 + cells, using flow cytometry after annexin V/PI staining. As shown in 
Effects of panobinostat or 5-azacytidine on the growth of progenies with abnormal karyotype
We examined whether karyotypic change was found by the addition of panobinostat or 5-azacytidine to the culture, using FISH analysis. ( Figure 4 ). reported that the mean C max of 581 patients with advanced hematologic and solid tumors who were treated with 20 mg panobinostat was 28.5 ± 3.5 nM. 17 According to a phase I study of oral once daily panobinostat (20 mg) in Japanese adult patients with advanced solid tumors, the mean C max on day 1 was 30.9 ± 8.6 nM. 18 Thus, the inhibitor may 
